cTAPcTAPcTAPcTAP
  • WHAT WE DO
  • WHO WE ARE
  • HOW WE DO IT
  • NEWS
  • CONTACT
  • IS cTAP FOR YOU?
    • Biopharmaceutical Companies
    • Scientific Leaders & Researchers
    • Patient Organizations

cTAP Publishes Comprehensive Analysis of NSAA

cTAP Publishes Comprehensive Analysis of NSAA

The collaborative Trajectory Analysis Project (cTAP), a multi-stakeholder, global coalition in Duchenne muscular dystrophy (DMD), has published research in the journal PLOS ONE providing quantitative insights to assist the design and analysis of clinical trials in patients with DMD.

READ FULL PRESS RELEASE ON BUSINESSWIRE: cTAP Publishes Comprehensive Analysis of the North Star Ambulatory Assessment (NSAA), a Newly Adopted Primary Outcome Measure in Clinical Trials of Patients with Duchenne Muscular Dystrophy

26
Sep 2019
News & Press

Read the latest

  • Prognostic factors for loss of ability to rise from supine in DMD
  • Suitability of external controls for drug evaluation in Duchenne muscular dystrophy
  • cTAP Study Shows Real-World, Natural History Data Comparable to Placebo Data from Clinical Trials in Duchenne Muscular Dystrophy
  • A prognostic model for 1 year change in 4SC
  • Deflazacort vs prednisone treatment for Duchenne muscular dystrophy

COLLABORATIVE TRAJECTORY
ANALYSIS PROJECT

Cambridge Innovative Center
One Broadway, Cambridge, MA 02142

T: 617-555-5555
E: info@ctap-duchenne.org

© 2021 Collaborative Trajectory Analysis Project. All rights reserved.

  • WHAT WE DO
  • WHO WE ARE
  • HOW WE DO IT
  • NEWS
  • CONTACT
  • IS cTAP FOR YOU?
    • Biopharmaceutical Companies
    • Scientific Leaders & Researchers
    • Patient Organizations